The rough road for rosiglitazone

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 15, Issue 2, 2008, Pages 113-117

  Goldfine, Allison B ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JOSLIN DIABETES CENTER   (United States)

Author keywords

Cardiovascular disease; Ischemic heart disease; Rosiglitazone; Type 2 diabetes

Indexed keywords

GLIBENCLAMIDE; INSULIN; METFORMIN; NITRATE; PIOGLITAZONE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; SULFONYLUREA; TOLBUTAMIDE; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ANGINA PECTORIS; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL OBSERVATION; CLINICAL PRACTICE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETIC PATIENT; DRUG APPROVAL; DRUG FATALITY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FLUID RETENTION; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; LIVER TOXICITY; LONG TERM CARE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMARKETING SURVEILLANCE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STROKE; WEIGHT GAIN; DIABETES MELLITUS; EDITORIAL; META ANALYSIS; RISK FACTOR; TIME;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; META-ANALYSIS AS TOPIC; RISK FACTORS; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 42449155965     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3282f8b483     Document Type: Review

References (18)

1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-2471. This key paper suggests an increased cardiovascular mortality risk in patients treated with rosiglitazone.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
4. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med 2007; 356:2522-2524.
5. Salsburg DS. The UGDP study. J Am Med Assoc 1971; 218:1704-1705.
6. The Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998; 116:874-886.
7. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, et al. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br Med J (Clin Res Ed) 1985; 290:811-815.
8. Dandona P, Bolger JP, Boag F, et al. Rapid development and progression of proliferative retinopathy after strict diabetic control. Br Med J (Clin Res Ed) 1985; 290:895-896.
9. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643-2653.
10. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-1289.
11. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427-2443.
12. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368:1096-1105.
13. Lubsen J, Poole-Wilson PA. The DREAM trial. Lancet 2006; 368:2050.
14. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005; 48:1726-1735.
15. Brooks MM, Frye RL, Genuth S, et al. Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol 2006; 97:9G-19G.
16. Johannes CB, Koro CE, Quinn SG, et al. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmacoepidemiol Drug Saf 2007; 16:504-512.
17. McAfee AT, Koro C, Landon J, et al. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007; 16:711-725.
18. Rosen CJ. The rosiglitazone story-lessons from an FDA Advisory Committee meeting. N Engl J Med 2007; 357:844-846.